Bicycle Therapeutics Limited Stock Price, News & Analysis

Bicycle Therapeutics (NASDAQ: BCYC) announced the presentation of a Trials in Progress poster for its Phase I/II clinical trial of BT7480 at the 2022 ASCO Annual Meeting in Chicago, IL, scheduled for June 5, 2022. BT7480 is a novel Bicycle TICA™ targeting Nectin-4 while agonizing CD137 in patients with advanced malignancies. The study aims to evaluate the therapeutic potential of BT7480 in addressing unmet medical needs in oncology. Additional details about the study will be available on their website following the presentation.

Bicycle Therapeutics (NASDAQ: BCYC) reported significant clinical progress in its oncology pipeline during Q1 2022, including promising interim data for the BT8009 Phase I clinical trial with a 50% overall response rate in patients with urothelial cancer. As of March 31, 2022, the company has $407.4 million in cash and equivalents, expected to fund operations through 2024. However, it reported a net loss of $27.6 million, or $(0.93) per share, compared to a loss of $16.2 million in Q1 2021.

Egle Therapeutics SAS has appointed Pierre Legault as Chairman and board member, effective March 2022. With over 35 years of experience in the biotech sector, his leadership is anticipated to enhance Egle's efforts in developing novel immunotherapies targeting regulatory T cells (Tregs) for oncology and autoimmune diseases. Mr. Legault's previous roles include Director at Syndax Pharmaceuticals and Chairman at Bicycle Therapeutics (BCYC), positioning him well to accelerate Egle's strategic initiatives.

Bicycle Therapeutics (NASDAQ: BCYC) announced interim Phase I results for BT8009, a second-generation BTC targeting Nectin-4, at the 2022 AACR Annual Meeting. The overall confirmed response rate was 50%, with one complete response among eight urothelial cancer patients at a 5.0mg/m² dosage. No dose-limiting toxicities were observed, and the tolerability profile remained favorable. Four of five responders are still on therapy after 24 weeks. The Phase I trial continues to explore additional dosing options. A conference call will provide further insights.

Bicycle Therapeutics (NASDAQ: BCYC) announced the presentation of interim Phase I results for BT8009, targeting Nectin-4, at the 2022 American Association for Cancer Research Annual Meeting. The oral presentation titled BT8009-100 Phase I/II Study will be on April 10, 2022, at 4:05 PM CT, presented by Meredith McKean from the Sarah Cannon Research Institute. Following the presentation, the company will hold a conference call on April 11, 2022, at 8:30 AM ET to discuss the findings.

Bicycle Therapeutics (NASDAQ: BCYC) announced updated preclinical results demonstrating the efficacy of its Bicycle® technology as a novel antiviral therapy against SARS-CoV-2. Presented at the 2022 Microbiology Society Annual Meeting in Dublin, the data showed that Bicycles bind to various epitopes of the SARS-CoV-2 spike protein and exhibit potent activity in vitro and in vivo. The research has received funding from InnovateUK, and Bicycle is optimistic about the potential of these small molecules in combating COVID-19 variants.

Bicycle Therapeutics (NASDAQ: BCYC) will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on April 13, 2022, at 8:45 a.m. ET. The event will be available via a live webcast on Bicycle's website, with an archived replay accessible for 90 days post-event. Bicycle Therapeutics specializes in pioneering therapeutics using its proprietary Bicycle technology, focusing on clinical-stage biopharmaceuticals that target underserved diseases. Current development includes BT5528, BT8009, BT7480, and BT1718 across various trials.

Bicycle Therapeutics (NASDAQ: BCYC) announced that interim Phase I results from the ongoing Phase I/II trial of BT8009, targeting Nectin-4, will be presented at the 2022 American Association for Cancer Research Annual Meeting in New Orleans from April 8-13. The company will discuss these results in a conference call on April 11, 2022, at 8:30 a.m. ET. Additionally, four abstracts are selected for presentation, including details on BT7480 and BCY6033, highlighting advancements in Bicycle's novel therapeutics.